- Sept. 12, 2019
-- With its recently published study "
Global TNF Alpha Inhibitors Market –
Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025"
, Infoholic Research forecasts
that the global TNF alpha inhibitors market will continue to grow, owing to increased spending on R&D by pharmaceutical companies, higher prevalence of chronic autoimmune diseases globally, and constant research to develop target-based biologics. Continuous development of biosimilars and evolving market opportunities are poised to support the market growth during the forecast period 2019–2025.
The global TNF alpha inhibitors market, by drug class, is segmented into adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Among these, adalimumab occupied a dominant share in 2018, and golimumab is expected to grow at a high CAGR during the forecast period 2019–2025. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made adalimumab the largest revenue contributor in 2018. Currently, many companies are heavily investing to develop innovative products and enjoy the first-mover's advantage in the market; this will be crucial at a point as soon as biologics lose their patents. Adalimumab has the highest number of ongoing clinical trials among various TNF alpha inhibitors, followed by certolizumab pegol.Access Full Report Summary
North America occupied a significant share in the TNF alpha inhibitors market in 2018, and Europe is also likely to grow at a high CAGR during the forecast period. Many companies, including Amgen, have filed the majority of their patents in the US, which provides them more extended exclusivity in North America. Growing R&D investments to develop new drugs and increasing efforts to accept biosimilars further make Europe the fastest-growing region.
Visit Infoholic Research (https://www.infoholicresearch.com/)
website for complete or sample report.